Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation

• Published in: International journal of clinical practice (Esher) Vol. 61; no. 4; pp. 702 - 710
• Main Authors: Llorca, P. M., Fernandez, J.-L.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2007; Blackwell
• Subjects: Adult and adolescent clinical studies; Antidepressive Agents, Second-Generation - economics; Antidepressive Agents, Second-Generation - therapeutic use; Biological and medical sciences; Citalopram - economics; Citalopram - therapeutic use; Cost-Benefit Analysis; Cyclohexanols - economics; Cyclohexanols - therapeutic use; Depression; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - economics; General aspects; Humans; Medical sciences; Meta-Analysis as Topic; Models, Econometric; Mood disorders; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Quality of Life; Randomized Controlled Trials as Topic; Serotonin Uptake Inhibitors - economics; Serotonin Uptake Inhibitors - therapeutic use; Treatment Outcome; Venlafaxine Hydrochloride; Mood disorder; Serotonin; Escitalopram; Controlled release form; Psychotropic; Depression; Catecholamine; Reuptake inhibitor; Selective serotonin reuptake inhibitor; Medicine; Treatment; Health economy; Formulation; Neurotransmitter; Dosage form; Antidepressant agent; Venlafaxine; Norepinephrine; Comparative study; Cost efficiency analysis

Summary Major depressive disorder (MDD), a prevalent and serious mental illness, is associated with a substantial disease and economic burden. Long‐term pharmacotherapy is often necessary; selective serotonin reuptake inhibitors (SSRIs) or the serotonin–noradrenaline reuptake inhibitor venlafaxine a...